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Background: Untreated advanced hepatocellular carcinoma (HCC) is linked to poor prognosis. While sorafenib is
the current recommended treatment for advanced HCC, radioembolisation (RE; also called selective internal
radiation therapy or SIRT) with yttrium-90 microspheres has shown efficacy in cohort studies. However, there are no
head-to-head trials comparing radiation therapy with yttrium-90 microspheres and sorafenib in advanced HCC. The
SARAH trial has been designed to compare the efficacy and safety of sorafenib therapy and RE using yttrium-90
resin microspheres (SIR-Spheres™; Sirtex Medical Limited, North Sydney, Australia) in patients with advanced HCC.
Quality of life (QoL) and cost-effectiveness will also be compared between therapies.
Methods/Design: SARAH is a prospective, randomised, controlled, open-label, multicentre trial comparing the efficacy
of RE with sorafenib in the treatment of patients with advanced HCC. The trial aims to recruit adults with a life expectancy
of >3 months, Eastern Cooperative Oncology Group (ECOG) performance status ≤1, and: advanced HCC according to the
Barcelona criteria (stage C) or recurrent HCC after surgical or thermoablative treatment who are not eligible for surgical
resection, liver transplantation or thermal ablation; or two rounds of failed chemoembolisation. Patients will be randomised
1:1 to receive either RE or sorafenib 400 mg twice daily. All patients will be monitored for between 12 and 48 months
following start of treatment. The primary endpoint of the SARAH trial is overall survival (OS). Secondary endpoints include:
adverse events, progression-free survival at 6 months; tumour response rate; general or liver disease-specific QoL scores;
and cost of each treatment strategy. Assuming an increase in median OS of 4 months with RE versus sorafenib therapy,
randomising at least 400 patients (200 in each treatment arm) will be sufficient for 80% power and a bilateral alpha risk of
5%; therefore, 440 patients will be enrolled to allow for 10% loss of patients due to ineligibility.
Discussion: The SARAH trial is the first randomised head-to-head study to compare RE with sorafenib in advanced HCC,
and will establish the potential role of RE in HCC treatment guidelines.
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The prevalence and incidence of hepatocellular carcin-
oma (HCC) is highly variable in different regions of the
world but the burden is predicted to increase in the
coming years [1]. In developed countries, early diagnosis
of HCC is possible in 30 to 60% of patients, and as a
result, HCC is often diagnosed in the advanced stage of
disease (stage C of the Barcelona Clinic Liver Cancer
classification – that is, ECOG performance status 1 to 2,
portal invasion or extrahepatic spread, and Child-Pugh
A-B). Curative treatment (by surgical resection, liver trans-
plantation or thermoablative treatment) is possible only in
a limited proportion of these patients [2], and many cases
of HCC progress to an advanced stage following locoregio-
nal treatment. In patients with untreated advanced HCC,
the prognosis is poor, with a median survival time of ap-
proximately 5 to 7 months, although this varies depending
on Child‐Pugh score [3-5].
The pivotal Sorafenib Hepatocellular carcinoma As-
sessment Randomized Protocol (SHARP) trial showed that
sorafenib (Nexavar™, Bayer HealthCare Pharmaceuticals,
Berlin, Germany) treatment significantly increased median
overall survival (OS) time by approximately 3 months ver-
sus placebo (10.7 months versus 7.9 months, respectively;
P <0.001) in patients with advanced HCC [6]. These find-
ings were subsequently confirmed in a randomised con-
trolled trial in the Asia-Pacific, which showed OS of
6.5 months in the sorafenib arm versus 4.2 in the placebo
arm (P <0.014) [7]. As a result of these data, sorafe-
nib is the current recommended first-line treatment for
advanced (Barcelona stage C) HCC [2]. However, while
sorafenib increased OS in the SHARP study, it did not im-
prove median time to symptomatic progression, and was
associated with an overall adverse‐effect incidence of 80%.
Adverse events experienced by >5% of patients in the
SHARP trial included diarrhoea (13.1%), asthenia (7.4%),
hand-foot skin reaction (7.0%), and erythema or desquam-
ation (5.4%); dose reductions and treatment interruptions
due to adverse effects occurred in 26% and 44% of cases,
respectively [6]. As such, there is a medical need for the
study of alternative treatment options for advanced HCC.
Radioembolisation (RE; also called selective internal
radiation therapy or SIRT) with SIR-Spheres™ (Sirtex
Medical Limited, North Sydney, Australia), which con-
tain the β-emitter yttrium-90, is one potential alternative
treatment of advanced HCC. RE enables targeted deliv-
ery of radiation to the tumours, while the surrounding
liver parenchyma is largely spared. A recent meta‐analysis
showed a high response rate to yttrium‐90 RE in HCC pa-
tients [8]. Population disparity prevented assessment of
OS in this meta-analysis but cohort studies of patients
with HCC receiving yttrium‐90 RE report median OS be-
tween 7 and 26.3 months [9-18]. Collectively, these data
suggest that the use of RE for advanced HCC warrantsfurther investigation, and might improve median OS with
fewer side effects and/or better quality of life (QoL) com-
pared with sorafenib.
To the authors’ knowledge, no controlled, prospective
trials have been published on the efficacy of RE in HCC
patients. For this reason, the SorAfenib versus Radioembo-
lisation in Advanced Hepatocellular carcinoma (SARAH)
trial has been designed as a prospective, randomised,
open-label, multicentre trial to compare the OS in patients
with advanced HCC receiving either RE with SIR-Spheres™
or sorafenib. Secondary objectives include comparisons be-
tween the treatment arms of other efficacy parameters, the
safety profile and tolerability, QoL and cost-effectiveness.
Methods/Design
The SARAH trial will be conducted in accordance with
the Declaration of Helsinki and current good clinical
practice guidelines, and all participating centres have ob-
tained the relevant ethics committee approval before pa-
tient enrolment (see Additional file 1).
Eligible population
The inclusion and exclusion criteria for the SARAH trial
are summarised in Table 1. Informed consent will be ob-
tained from each participant.
Overview of trial design
SARAH is a prospective, randomised open-label, multi-
centre trial comparing RE and sorafenib in patients with
advanced HCC. In SARAH, the aim will be to recruit a
minimum of 440 patients over a period of 24 months
across 28 centres in France. Centres will be chosen
based on their potential to recruit a high number of pa-
tients, and the expertise in intra-arterial treatment, and
will receive special training with RE. Eligible patients will
be stratified 1:1 to receive either systemic therapy with
oral sorafenib (control arm) or RE with SIR-Spheres™
(RE arm; Figure 1).
Randomisation
Eligible patients will be randomised 1:1. The random-
isation will be stratified by centre, Eastern Cooperative
Oncology Group (ECOG) score (0 versus 1), the presence
or absence of macroscopic vascular invasion seen on im-
aging (obstruction of the portal vein or its branches) and
previous chemoembolisation failure. The list will be bal-
anced by different sized blocks and randomly alternated.
The data coordination centre will prepare the randomisa-
tion list before enrolment begins.
Treatments
In the sorafenib arm, patients will receive oral treatment
with sorafenib (400 mg twice daily) beginning in the
week following randomisation (the first day of receiving
Table 1 Patient eligibility criteria for SARAH trial
Inclusion criteria Exclusion criteria
• Written informed consent provided • Other primary tumour except for basal cell carcinomas or superficial
bladder cancers
• Aged ≥18 years
• Extrahepatic metastases except non-specific pulmonary tumours <1 cm
and abdominal lymph nodes <2 cm• Histologically or cytologically confirmed diagnosis, or AASLD criteria for
the diagnosis, of HCC and at least one measureable lesion on CT
according to RECIST criteria • Previously treated advanced HCC (excluding chemoembolisation*)
• Advanced liver disease with a Child-Pugh score > B7 or active
digestive haemorrhage or encephalopathy or refractory ascites
• Patients not eligible for surgical resection, liver transplantation or
thermoablation who have advanced HCC according to the Barcelona criteria
(stage C), with or without portal invasion OR patients with recurrent HCC
(new lesion in a different place) after surgical or thermoablative treatment
who are not eligible for any other treatment; OR patients in whom
chemoembolisation has failed after two rounds – treatment failure is
defined as the absence of objective response in the treated nodule after
two rounds (objective response according to the modified RECIST
criteria and/or EASL criteria)
• Pregnant or breastfeeding women
• Allergy to contrast agents
• Contraindication to hepatic artery catheterisation, such as severe
peripheral arterial disease precluding catheterisation
• Mental illness or other psychological disorder affecting the
informed consent
• Patient unable or unwilling to comply with the treatment and
follow-up required by the study
• Unable to take oral medication• ECOG performance status ≤1
• Adequate haematological function: haemoglobin ≥9 g/100 mL,
neutrophils ≥1,500/mm3, platelets ≥50,000/mm3
• Adequate kidney function: creatinine <150 μmol/L
• Bilirubin ≤50 μmol/l, AST or ALT ≤5 x ULN, INR ≤1.5
• If liver cirrhosis, Child-Pugh A-B7
• Affiliated to a social security scheme or beneficiary
*Patients who have not responded to chemoembolisation but who meet the other selection criteria will be included in this study. AASLD, American Association
for the Study of Liver Diseases; ALT, alanine aminotransferase; AST, aspartate transaminase; CT, computed tomography; EASL, European Association for the Study
of the Liver; ECOG, Eastern Cooperative Oncology Group; HCC, hepatocellular carcinoma; INR, international normalised ratio; RECIST, response evaluation criteria in
solid tumours; ULN, upper limit of normal.
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sions and dose reductions (to 400 mg/d) will be permitted
in case of adverse events (based on the SHARP study [6])
and at the treating practitioner’s discretion. Treatment
may be resumed once the adverse events have been re-
solved, with incremental doses up to 400 mg twice daily.
In the RE arm, patients randomised to RE will require a
hepatic angiogram, and a liver-to-lung shunt pre-assessment
with technetium-99 m (99mTc)-marked human serum al-
bumin in order to determine their suitability for the RE
procedure. Accessory tumoural vascular branches and
extrahepatic vascular branches will be embolised using
thrombogenic coils or vascular plugs in order to isolate
the arterial supply of the afferent vessel that vascularisesFigure 1 Overview of the SARAH trial design. ECOG, Eastern Cooperativthe tumour. A catheter will then be placed in the afferent
vessel that vascularises the tumour, and 150 to 180 MBq
of 99mTc-marked human serum albumin will be injected.
The injection rate and catheter position will mimic the an-
ticipated RE procedure. After the injection, the patient will
have the pulmonary shunt evaluated using a dual-head
gamma camera or single-photon emission computed tom-
ography (SPECT)/computed tomography (CT). The pre-
scribed activity of SIR-Spheres™ will then be calculated
based on the patient’s body surface area and the percent-
age tumour involvement as described by Kennedy et al.
[19]. Patients who would receive a dose in the lungs
higher than 25 Gy based on the liver-to-lung shunt pre-
assessment will not receive RE, but will remain in thise Oncology Group; RE, radioembolisation.
Table 2 SARAH trial assessment schedule
Visits Enrolment/randomisation D0 D15 M1 M2 M3 M4 M5 M6 M7 M8 M9 End of participation
Identification X
Verification of selection criteria X
Consent signature X
Initial assessment – history X
CT scan X X X X X X
CT perfusion X X X X
Laboratory tests X X X X X X X X X X X X X
Classification X X X X X X X X X X X
Clinical examination X X X X X X X X X X
Quality of life questionnaires X X X X X X
Preparatory angiography X
Scintigraphy X
RE X
Start of sorafenib treatment X
Retreatment* X X X X X X X X X
Cancer progression monitoring X X X X X X X X X X
Sorafenib monitoring X X X X X X X X X X
Concomitant medication X X X X X X X X X X
Adverse events X X X X X X X X X X
*Timing of retreatment depends upon type of retreatment (see text). CT, computed tomography; D, day; M, month; RE, radioembolisation.
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Patients who are eligible for RE will commence treatment
between the second and fifth week after randomisation
with a single session of treatment (the day on which RE is
administered is defined as D0 in Table 2). In patients with
bilobar involvement, contralateral RE will be administered
within 30 to 60 days. In order to avoid premature retreat-
ment with RE of any lobe due to late tumour response,
retreatment with RE will only be considered beyond
3 months from D0 in the absence of objective response or
if there is significant progression on imaging (stable or
progressor according to the response evaluation criteria in
solid tumours (RECIST) or European Association for the
Study of the Liver (EASL)) in the treated region (same
tumour or new tumour). Retreatment with RE will also be
considered beyond 6 weeks in the event of partial failure
of the initial treatment due to an identified correctible
cause or if an insufficient tumour dose was delivered.
Trial assessments
The last enrolled patient will be followed up for 12 months
after the start of treatment (D0). All other patients will be
followed up until the final visit of the last enrolled patient.
Patients will therefore be followed up for a maximum of
48 months and a minimum of 12 months following start
of treatment. All patients will be assessed by the schedule
summarised in Table 2. Treatment will be discontinued if
the patient withdraws consent, if the treating physiciandeems it necessary for medical reasons or if a serious ad-
verse event occurs - after discontinuation, patients should
be assessed by CT as soon as possible to assess response
to treatment.
Outcome measures
The primary endpoint of the SARAH trial is OS. Secondary
endpoints include: adverse events rate, progression-free
survival (PFS) at 6 months according to RECIST [20],
modified RECIST, EASL and Choi criteria; tumour re-
sponse rate; general or liver disease-specific QoL scores;
and cost of each strategy.
Cost endpoints are: the cost of RE from the hospital
perspective; the average cost per patient from the payer’s
perspective; and the incremental cost-effectiveness or
cost-utility ratio.
Outcome definitions
 OS is defined as the time from the date of
randomisation to death from any cause.
 PFS - the time from the date of first treatment to
disease progression - and tumour response rate
(complete response, partial response, stability, or
progression) will be determined from serial CT scans
using RECIST, modified RECIST, EASL criteria for
HCC, and Choi criteria [21]. Radiological examinations
will be conducted by abdominal radiologists at each
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radiological examinations.
 The general and liver disease-specific quality of life
scores will be calculated using the European
Organisation for Research and Treatment of Cancer
(EORTC) quality of life questionnaire (QLQ-C30)
version 3 and the HCC-specific QLQ-HCC 18
questionnaire [22].
 Adverse events will be reported according to
National Cancer Institute criteria (National Cancer
Institute Common Terminology criteria for Adverse
Events (NCI CTCAE) Version 4.0) [23].
The cost of therapy from the hospital’s perspective will
be estimated by including all the resources that are dir-
ectly attributable to the procedure (that is, equipment,
tests, total work time, and so on), which will be assigned
a value based on the purchase price by the hospital. The
mean overall cost per patient from the payer’s perspec-
tive will include the relative stay index and readmissions
during the patient’s follow-up period. Calculation of the
incremental cost-effectiveness ratio per year of survival or
the incremental cost-utility ratio between RE and sorafenib
will be complemented by the bootstrap resampling method
and an acceptability curve for the cost-effectiveness ratio.
Sample size calculation and statistical considerations
Based on OS data with sorafenib from the SHARP study
[6] and with yttrium-90 RE reported in the literature
[9,11-15], the number of patients required for randomisa-
tion to detect a clinically relevant increase (4 months) in
OS time with RE versus sorafenib was determined as 400
patients (200 patients in each treatment arm). This trans-
lates to an expected median OS time of 10.7 months in the
sorafenib group and 15 months in the RE group, with an
accrual period of 24 months and follow-up of 12 months.
These guarantee a power of 80% with a bilateral alpha risk
of 5%. Estimating that up to 10% of patients that are re-
cruited will not fulfil the criteria of eligibility for random-
isation, we aimed to enrol 440 patients.
A Data Monitoring Committee (DMC) will regularly
review the toxicity data to assess the safety profile of the
treatment (including serious adverse events and mortal-
ity). The first intermediate analysis will take place once
30 patients have been followed up for at least 2 months
in each treatment arm, after which the DMC will con-
vene every 6 months.
Statistical analysis
Results will be reported according to the Consolidated
Standards of Reporting Trials (CONSORT) statement.
An ITT analysis will be performed, keeping patients in
their randomisation group and including protocol devia-
tions. A ‘per-protocol’ sensitivity analysis will also beperformed. A study flowchart will be provided, including
the number of patients who: are eligible; are randomised
to receive treatment; are followed up; withdraw from the
study; and are lost to follow-up. Major protocol devia-
tions and the reasons for withdrawal from the study will
be described.
The Kaplan and Meier method will be used to calculate
survival (OS and PFS). The comparison of survival rates at
12 months between the two treatment groups will be per-
formed using the log rank test (Mantel-Haenszel version).
In addition, the treatment effect, once adjusted for the
stratified randomisation factors, will be calculated via:
(1) a stratified log rank analysis; and (2) a Cox’s regression
model.
The median survival times (OS and PFS) in both treat-
ment groups will be calculated, along with the confi-
dence interval associated with the difference or with the
median survival time ratio [24].
Toxicity will be reported according to NCI CTCAE
Version 3.0, with particular reference to the proportion
of patients experiencing grade 3/4 toxicity in each treat-
ment arm.
The objective response will be determined via the
RECIST and modified (m)RECIST criteria, the EASL
criteria for HCC, and the Choi criteria, and a compari-
son will be made between the two treatment groups
using the ‘best response during follow-up’ criterion.
The response rates will be calculated by comparing the
number of patients who responded during follow-up
(complete or partial response) with the total number
of randomised patients in each group. The related
confidence intervals will be calculated and compared
between the two groups using Pearson’s chi-squared
test.
Economic evaluation and statistical methods
The costs of both therapies will be compared using the
Student’s t test. Uncertainty over the cost and effectiveness
differentials between the two groups will be measured
using the bootstrap resampling method. Cost-effectiveness
will be measured using the incremental cost-effectiveness
ratio per life year gained. Markov modelling will be
used to calculate the cost-effectiveness ratio by simu-
lating patient follow-up beyond the end of the study.
Discussion
The SARAH trial will compare the efficacy and safety of
RE with that of sorafenib in the treatment of advanced
HCC (see Additional file 2). To the authors’ knowledge,
no prospective, controlled trials have been published, ran-
domised or otherwise, on the efficacy of yttrium-90 RE in
patients with HCC.
Sorafenib has been chosen as the control in the SARAH
trial as it is the current recommended first-line treatment
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OS is significantly increased by nearly 3 months with
sorafenib versus placebo [6,7]. However, the incidence of
adverse events was high (80%) in the SHARP trial and
there was no improvement in time to symptomatic pro-
gression with sorafenib therapy [6]. Attempts to improve
outcomes for patients with advanced HCC on sorafenib
by combination with other drug therapies have had lim-
ited success when compared with sorafenib alone [26-30].
Sorafenib combination therapy with transarterial che-
moembolisation (TACE) has shown promise in patients
with unresectable HCC [31], but is not currently recom-
mended for advanced HCC. Indeed, combination therapy
with sorafenib is not currently recommended outside the
clinical trial setting for advanced HCC [27], and there is a
need for an efficacious alternative with a favourable safety
profile. RE with yttrium-90 is also indicated as a first-line
treatment for unresectable HCC in a number of countries,
and is associated with a high response rate in HCC pa-
tients (78 to 89% across 14 studies) [8]. Thus a head-to-
head, prospective trial of these two treatments warrants
investigation.
Some aspects of the SARAH study design are worth
further discussion. The inclusion criteria are similar to the
SHARP trial, except extrahepatic dissemination is not
permitted in the SARAH study as RE is a localised ther-
apy. Although previous treatment for advanced HCC is an
exclusion criterion, prior chemoembolisation is permitted
as patients failing chemoembolisation would be indicated
for sorafenib therapy. Eligible patients in the SARAH
study have also been stratified according to ECOG
score, as this is an independent prognostic factor for
survival in patients with HCC treated with RE or sorafenib
[10,32]. In addition, patients will be stratified by presence
or absence of macroscopic vascular involvement as vascu-
lar involvement has been associated with poor prognosis
in patients with HCC [10,13,33].
In the SARAH trial, OS has been chosen as the pri-
mary endpoint as it is a more robust measure than PFS,
and the SHARP trial demonstrated the efficacy of sorafenib
based on this criterion. Moreover, the kinetics of tumour
progression, as assessed from imaging techniques, is differ-
ent between RE and sorafenib, rendering OS the best op-
tion for comparison between arms in this trial. An Asian
study with similar inclusion criteria has now commenced,
which compares sorafenib with RE in patients with locally
advanced HCC [34], and could be used for meta-analysis
in the future.
In addition to efficacy analyses, the SARAH trial offers
the possibility of rigorously confirming the toxicity
caused by sorafenib versus RE in patients with advanced
HCC. This is important as the cardiovascular toxicity of
sorafenib has been highlighted in a meta-analysis of
cancer patients (predominantly renal carcinoma) [35],but was not a common complication in the SHARP
study [6]. The SARAH trial will also offer the oppor-
tunity to conduct ancillary studies (for example,
dosimetry and CT perfusion), and compare the cost of
each treatment. A definitive economic evaluation of
sorafenib therapy versus RE for advanced HCC is not
currently available. It is therefore useful to: conduct a
study using national data to establish the value of the
resources used; take the specificities of local oncology
practices into account; and compare sorafenib treatment
to an up-to-date therapy, RE.
Limitations to the SARAH study design have been
combated where feasible. While blinding is not possible
due to the treatment methods, the potential biases caused
by the lack of blinding have been minimised by the choice
of OS as a robust primary endpoint. In addition, it is
planned that an independent group of radiologists will
perform a blind review of the imaging in order to guaran-
tee the absence of bias regarding PFS.
The results from the SARAH trial should further the
understanding of RE and determine the optimal treat-
ment modality in advanced HCC. In addition, the data
generated from this study may help to place RE into
future consensus guidelines.
Trial status
The SARAH trial is currently recruiting participants.
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Additional file 1: Approval of ethics committee for all participating
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Additional file 2: Brief summary.
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